Chemoprevention of colorectal cancer -experimental and clinical aspects

Journal of Medical Investigation

Volumn 56, Issue 1-2, 2009, Pages 1-5

  Takayama, Tetsuji ^a   Goji, Takahiro ^a   Taniguchi, Tatsuya ^a   Inoue, Atsushi ^a  

^a UNIVERSITY OF TOKUSHIMA   (Japan)

Author keywords

Aberrant crypt foci; Chemoprevention; Colorectal cancer

Indexed keywords

21 (4 DIETHYLAMINOMETHYL 2 METHOXYPHENOXY) 7ALPHA METHYL 19 NORPREGNA 1,3,5(10) TRIEN 3 OL; 4 (3 DIMETHYLAMINOPROPYLAMINO) 2 (4 METHOXYSTYRYL)QUINAZOLINE; 4 [4 (4' CHLORO 2 BIPHENYLYLMETHYL) 1 PIPERAZINYL] N [4 [3 DIMETHYLAMINO 1 (PHENYLTHIOMETHYL)PROPYLAMINO] 3 NITROBENZENESULFONYL]BENZAMIDE; 6 [3 (4 CHLORO 2 METHYLPHENYLSULFONYLAMINOMETHYL)BICYCLO[2.2.2]OCTAN 2 YL] 5 HEXENOIC ACID; ACETYLSALICYLIC ACID; ANTINEOPLASTIC AGENT; BEVACIZUMAB; BORTEZOMIB; CELECOXIB; CETUXIMAB; COLECALCIFEROL DERIVATIVE; CURCUMIN; CYCLOOXYGENASE 2 INHIBITOR; EFLORNITHINE; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; ETODOLAC; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NONSTEROID ANTIINFLAMMATORY AGENT; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PIOGLITAZONE; PLACEBO; PRINOMASTAT; RESVERATROL; RETINOID DERIVATIVE; ROSIGLITAZONE; SULINDAC; TIPIFARNIB; UNINDEXED DRUG; VORINOSTAT;

ADENOMATOUS POLYP; ANTINEOPLASTIC ACTIVITY; CANCER GROWTH; CANCER INHIBITION; CANCER MORTALITY; CEREBROVASCULAR ACCIDENT; CHEMOPROPHYLAXIS; CLINICAL TRIAL; COLON ADENOMA; COLON POLYP; COLORECTAL ADENOMA; COLORECTAL CANCER; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG TARGETING; EPIGENETICS; FAMILIAL POLYPOSIS; GENE MUTATION; HEART INFARCTION; HUMAN; NONHUMAN; REVIEW; SIGNAL TRANSDUCTION;

EID: 63349102350     PISSN: 13431420     EISSN: None     Source Type: Journal    
DOI: 10.2152/jmi.56.1     Document Type: Review

References (16)

1. Ferlay J, Autier P, Moniol M, et al: Estimates of the cancer incidence and mortality in Europe in 2006. Ann Oncol 18: 581-592, 2007
2. Lindström CG, Rosengren JE, Ekberg O: Experimental colonic tumours in the rat. III. Induction time, distribution and appearance of induced tumours. Acta Radiol Diagn (Stockh) 19: 799-816, 1978
3. Su LK, Kinzler KW, Vogelstein B, Preisinger AC, Moser AR, Luongo C, Gould KA, Dove WF: Multiple intestinal neoplasia caused by a mutation in the murine homolog of the APC gene. Science 256: 668-670, 1992
4. Oshima M, Oshima H, Kitagawa K, Kobayashi M, Itakura C, Taketo M: Loss of Apc heterozygosity and abnormal tissue building in nascent intestinal polyps in mice carrying a truncated Apc gene. Proc Natl Acad Sci USA 92: 4482-4486, 1995
5. Bird RP: Observation and qualification of aberrant crypts in the murine colon treated with a colon carcinogen: preliminary findings. Cancer Lett 37: 147-51, 1987
6. Takayama T, Miyanishi K, Hayashi T, Sato Y, Niitsu Y: Colorectal cancer: genetics of development and metastasis. J Gastroenterol 41: 185-92, 2006
7. Kelloff GJ, Bast RC Jr, Coffey DS, D'Amico AV, Kerbel RS, Park JW, Ruddon RW, Rustin GJ, Schilsky RL, Sigman CC, Woude GF: Biomarkers, surrogate end points, and the acceleration of drug development for cancer prevention and treatment: an update prologue. Clin Cancer Res 10: 3881-4, 2004
8. Weinstein IB: Cancer. Addiction to oncogenes-the Achilles heal of cancer. Science 297(5578): 63-4, 2002
9. Osawa E, Nakajima A, Wada K, Ishimine S, Fujisawa N, Kawamori T, Matsuhashi N, Kadowaki T, Ochiai M, Sekihara H, Nakagama H: Peroxisome proliferator-activated receptor gamma ligands suppress colon carcinogenesis induced by azoxymethane in mice. Gastroenterology 124: 361-7, 2003
10. Oshima M, Dinchuk JE, Kargman SL, Oshima H, Hancock B, Kwong E, Trzaskos JM, Evans JF, Taketo MM: Suppression of intestinal polyposis in Apc delta716 knockout mice by inhibition of cyclooxygenase 2 (COX-2). Cell 87: 803-9, 1996
11. Giardiello FM, Hamilton SR, Krush AJ, Piantadosi S, Hylind LM, Celano P, Booker SV, Robinson CR, Offerhaus GJ: Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis. N Engl J Med 328: 1313-6, 1993
12. Ladenheim J, Garcia G, Titzer D, Herzenberg H, Lavori P, Edson R, Omary MB: Effect of sulindac on sporadic colonic polyps. Gastroenterology 108: 1083-7, 1995
13. Arber N, Eagle CJ, Spicak J, Rácz I, Dite P, Hajer J, Zavoral M, Lechuga MJ, Gerletti P, Tang J, Rosenstein RB, Macdonald K, Bhadra P, Fowler R, Wittes J, Zauber AG, Solomon SD, Levin B: Celecoxib for the prevention of colorectal adenomatous polyps. N Engl J Med 355: 885-95, 2006
14. Bertagnolli MM, Eagle CJ, Zauber AG, Redston M, Solomon SD, Kim K, Tang J, Rosenstein RB, Wittes J, Corle D, Hess TM, Woloj GM, Boisserie F, Anderson WF, Viner JL, Bagheri D, Burn J, Chung DC, Dewar T, Foley TR, Hoffman N, Macrae F, Pruitt RE, Saltzman JR, Salzberg B, Sylwestrowicz T, Gordon GB, Hawk ET: APC Study Investigators. Celecoxib for the prevention of sporadic colorectal adenomas. N Engl J Med 355: 873-84, 2006
15. Takayama T, Katsuki S, Takahashi Y, Ohi M, Nojiri S, Sakamaki S, Kato J, Kogawa K, Miyake H, Niitsu Y: Aberrant crypt foci of the colon as precursors of adenoma and cancer. N Engl J Med 339: 1277-84, 1998
16. Kukitsu T, Takayama T, Miyanishi K, Nobuoka A, Katsuki S, Sato Y, Takimoto R, Matsunaga T, Kato J, Sonoda T, Sakamaki S, Niitsu Y: Aberrant crypt foci as precursors of the dysplasiacarcinoma sequence in patients with ulcerative colitis. Clin Cancer Res 14: 48-54, 2008